| Schedule of operating segments |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the three months ended March 31, 2026: | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | Cost of revenues | | | - | | | - | | | - | | | - | | | - | Gross profit | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | Research and development | | | 1,645,097 | | | 2,550 | | | 89,414 | | | 45,239 | | | 1,782,300 | General and administrative | | | - | | | - | | | 1,025,471 | | | 77,067 | | | 1,102,538 | Adjusted loss from operations | | | (1,645,097) | | | (2,550) | | | (1,114,885) | | | (122,306) | | | (2,884,838) | Share-based compensation | | | 44,470 | | | - | | | 76,738 | | | (121,208) | | | - | Depreciation and amortization | | | 659 | | | 110 | | | 329 | | | (1,098) | | | - | Loss from operations | | | (1,690,226) | | | (2,660) | | | (1,191,952) | | | - | | | (2,884,838) | Other income, net | | | - | | | - | | | 59,873 | | | - | | | 59,873 | Net loss before income taxes | | $ | (1,690,226) | | $ | (2,660) | | $ | (1,132,079) | | $ | - | | $ | (2,824,965) |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the three months ended March 31, 2025: | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | Cost of revenues | | | - | | | - | | | - | | | - | | | - | Gross profit | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | Research and development | | | 1,750,602 | | | 58,335 | | | 104,990 | | | 27,753 | | | 1,941,680 | General and administrative | | | - | | | - | | | 1,048,374 | | | 36,454 | | | 1,084,828 | Adjusted loss from operations | | | (1,750,602) | | | (58,335) | | | (1,153,364) | | | (64,207) | | | (3,026,508) | Share-based compensation | | | 26,488 | | | 840 | | | 36,271 | | | (63,599) | | | - | Depreciation and amortization | | | 364 | | | 61 | | | 183 | | | (608) | | | - | Loss from operations | | | (1,777,454) | | | (59,236) | | | (1,189,818) | | | - | | | (3,026,508) | Other income, net | | | - | | | - | | | 75,240 | | | - | | | 75,240 | Net loss before income taxes | | $ | (1,777,454) | | $ | (59,236) | | $ | (1,114,578) | | $ | - | | $ | (2,951,268) |
Reconciliation to Consolidated Loss Before Income Taxes The following table provides a reconciliation of total segment loss to consolidated loss before income taxes for the three months ended March 31: | | | | | | | | | 2026 | | 2025 | Loss from operations - reportable segments | | $ | (1,692,886) | | $ | (1,836,690) | Loss from operations - corporate | | | (1,191,952) | | | (1,189,818) | Interest income, net | | | 61,389 | | | 76,028 | Other expense, net | | | (1,516) | | | (788) | Net loss before income taxes | | $ | (2,824,965) | | $ | (2,951,268) |
Segment Assets The Company’s total assets by segment as of March 31, 2026, are presented below: | | | | | | | | | | | | | | | Specialized BioTherapeutics | | Public Health
Solutions | | Corporate | | Consolidated | Total assets | | $ | 277,383 | | $ | 2,558 | | $ | 6,642,699 | | $ | 6,922,640 |
The Company’s total assets by segment as of March 31, 2025, are presented below: | | | | | | | | | | | | | | | Specialized BioTherapeutics | | Public Health Solutions | | Corporate | | Consolidated | Total assets | | $ | 110,793 | | $ | 1,835 | | $ | 7,633,492 | | $ | 7,746,120 |
|